LOS ANGELES & MIAMI--(BUSINESS WIRE)--CompuMed, Inc. (OTCBB: CMPD) (www.compumed.net) today announced a landmark program in pediatric screening services, CardioGramKids™, teaming with the highly respected Department of Pediatrics at the University of Miami Miller School of Medicine to provide electrocardiogram (ECG) screening services to children and teenagers prior to prescribing or taking psychotropic medications, including stimulants. CompuMed will remotely interpret ECGs on pediatric patients in this first-of-its-kind program to detect heart abnormalities prior to therapy. CompuMed and the University of Miami have launched this program in response to the American Heart Association and other leading groups that have expressed concern regarding reports of sudden death in children and adolescents treated with stimulants and other psychotropic medications for conditions such as attention deficit hyperactivity disorder, commonly referred to as ADHD. Medical journals have long reported concerns regarding the appropriateness of such therapy without screening at risk patients.
